Goat Anti-Mouse IgG2a heavy chain (ab9163)
Key features and details
- Goat Anti-Mouse IgG2a heavy chain
- Host species: Goat
- Suitable for: ELISA, Immunodiffusion, Immunoelectrophoresis, WB
Related conjugates and formulations
製品の概要
-
製品名
Goat Anti-Mouse IgG2a heavy chain
IgG2a 二次抗体 製品一覧 -
由来種
Goat -
ターゲット生物種
Mouse -
特異性
The affinity purified anti IgG2a only reacts with mouse IgG2a by immunoelectrophoresis and double diffusion when tested at 1 mg/ml against all mouse immunoglobulin classes and subclasses at 1 mg/ml. -
アプリケーション
適用あり: ELISA, Immunodiffusion, Immunoelectrophoresis, WBmore details -
免疫原
Goats were immunized with highly purified mouse IgG2a in Freund’s adjuvant
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
バッファー
pH: 7.20 -
Concentration information loading...
-
精製度
Immunogen affinity purified -
特記事項(精製)
The antiserum was solid phase absorbed to make it IgG2a heavy chain specific and the anti IgG2A subsequently immunoaffinity purified off an IgG2a immunoabsorbant. -
ポリ/モノ
ポリクローナル -
研究分野
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab9163の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
ELISA |
Use at an assay dependent concentration.
|
|
Immunodiffusion |
Use at an assay dependent concentration.
|
|
Immunoelectrophoresis |
Use at an assay dependent concentration.
|
|
WB |
Use at an assay dependent concentration.
|
特記事項 |
---|
ELISA
Use at an assay dependent concentration. |
Immunodiffusion
Use at an assay dependent concentration. |
Immunoelectrophoresis
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. |
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
Datasheet download
参考文献 (1)
ab9163 は 1 報の論文で使用されています。
- Fradkin AH et al. Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins. J Pharm Sci 100:4953-64 (2011). PubMed: 21721003